Company news

Novavax, Inc. news in 2022

Novavax, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Novavax to Participate in BofA Securities 2022 Healthcare Conference

May 3, 2022

Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022

May 1, 2022

Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial

April 21, 2022

Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine

April 19, 2022

Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan

April 18, 2022

Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases

April 17, 2022

Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine

April 12, 2022

Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand

April 7, 2022

Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)

March 30, 2022

Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine

March 24, 2022

Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India

March 21, 2022

Novavax Announces Launch of Global Vaccine Education Programs

March 9, 2022

Novavax to Participate in Cowen's 42nd Annual Health Care Conference

March 1, 2022

Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights

February 27, 2022

Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial

February 27, 2022

Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 28, 2022

February 20, 2022

Health Canada Authorizes Novavax COVID-19 Vaccine

February 16, 2022

Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine

February 13, 2022

Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland

February 13, 2022

Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference

February 10, 2022

Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial

February 9, 2022

New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine

February 2, 2022

Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*

February 2, 2022

Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine

January 30, 2022

Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine

January 27, 2022

Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine

January 18, 2022

South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine

January 11, 2022

Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa

January 9, 2022

Novavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

← Newer news releases

Calls in 2022

Decks in 2022